GGrantIndex
Sort

25,944 grants matching neurodegeneration

DEGENERATIVE AND DEMENTING DISEASES OF AGING

$1,991,547
University Of California San Francisco · P01 · FY2002 · AG

Traumatic Brain Injury and Repetitive Head Impacts: Contributions to AD/ADRD and CTE Neuropathology and Resulting Clinical Syndromes

$1,989,941
Ann Carolyn McKee · Boston University Medical Campus · U54 · FY2022 · NS

The UCLA Udall Parkinson Disease Center of Excellence

$1,989,798
Marie-Francoise S Chesselet · University Of California Los Angeles · P50 · FY2010 · NS

CONNECT-TBI

$1,989,272
Douglas Hamilton Smith · University Of Pennsylvania · U54 · FY2019 · NS

Potassium Channels and Dendritic Function in Hippocampal Pyramidal Neurons

$1,987,350
Dax A Hoffman · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2021 · HD

First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD)

$1,984,624
Eti Yoles · Immunobrain Checkpoint Inc. · R01 · FY2021 · AG

Longitudinal validation of retinal biomarkers against cerebral imaging in preclinical Alzheimer's disease

$1,984,309
Jessica Alber · University Of Rhode Island · R01 · FY2025 · AG

Cell and molecular pathobiology of Alzheimer's Disease

$1,983,838
Ralph A. Nixon · Nathan S. Kline Institute For Psych Res · P01 · FY2009 · AG

Vascular contribution to white matter lesions and motor dysfunction in AD and ADRD

$1,983,762
Hyung Jin Ahn · Rutgers Biomedical And Health Sciences · RF1 · FY2022 · AG

Epidemiology of Biomarkers of Risk and Progression in LOAD

$1,982,531
Richard Mayeux · Columbia University Health Sciences · R01 · FY2011 · AG

Aging, the retromer complex and the neurobiology of Alzheimer's disease

$1,981,250
Domenico Pratico · Temple Univ Of The Commonwealth · RF1 · FY2017 · AG

Vps35 dysregulation, a mechanism of AD-like neurodegeneration and dementia in Down syndrome

$1,981,250
Domenico Pratico · Temple Univ Of The Commonwealth · RF1 · FY2017 · AG

Small molecule inhibitors of CAPON-induced tau aggregation

$1,980,378
Moustafa Gabr · Weill Medical Coll Of Cornell Univ · RF1 · FY2024 · AG

Single-cell transcriptomic and epigenomic analysis of brain cell vulnerabilities to tauopathies in early AD impacted brain regions

$1,979,459
Xiangmin Xu · University Of California-Irvine · R01 · FY2025 · AG

Epidemiology of Biomarkers of Risk and Progression in LOAD

$1,978,440
Richard Mayeux · Columbia University Health Sciences · R01 · FY2010 · AG

CELL AND MOLECULAR PATHOBIOLGY OF ALZHEIMER'S DISEASE

$1,975,994
Ralph A. Nixon · Nathan S. Kline Institute For Psych Res · P01 · FY2012 · AG

CELL AND MOLECULAR PATHOBIOLGY OF ALZHEIMER'S DISEASE

$1,975,994
Ralph A. Nixon · Nathan S. Kline Institute For Psych Res · P01 · FY2014 · AG

Immunometabolic regulation after CNS injury

$1,975,262
Krishnan M. Dhandapani · Augusta University · RF1 · FY2023 · NS

Studies in Alzheimer's disease and Neurodegenerative Diseases

$1,975,214
Dimitrios Kapogiannis · National Institute On Aging · ZIA · FY2018 · AG

Degenerative and Dementing Diseases of Aging

$1,972,358
Stanley B Prusiner · University Of California, San Francisco · P01 · FY2015 · AG

Epidemiology of Biomarkers of Risk and Progression in LOAD

$1,971,743
Richard Mayeux · Columbia University Health Sciences · R01 · FY2012 · AG

Chemical design of amyloid targeting fluorescent probes

$1,969,999
Emmanuel A Theodorakis · University Of California, San Diego · RF1 · FY2018 · AG

Cell Death Regulation by Pro-Apoptotic BOK in Tauopathies

$1,969,620
Samuel G Katz · Yale University · RF1 · FY2024 · NS

Nerve growth factor (NGF) metabolic dysfunction as a marker of cognitive decline in autosomal dominant Alzheimer's disease

$1,969,396
Yakeel T. Quiroz · Massachusetts General Hospital · RF1 · FY2022 · AG

The UCLA UDALL Parkinson Disease Center of Excellence

$1,967,910
Marie-Francoise S Chesselet · University Of California Los Angeles · P50 · FY2007 · NS